VivoSim Labs to Add Rat Liver Model to NAMkind Platform
https://www.globenewswire.com/news-release/20...tform.html
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement its existing NAMkind™ human liver platform and expand the Company’s liver toxicology capabilities.
The new model is designed to address a longstanding challenge in drug development: toxicity observed in rats does not always translate to humans.
VivoSim’s current human liver model is designed to identify human toxicity that may not appear in animal studies. The planned rat model would add the reverse capability, helping sponsors determine when an adverse finding in rats may be species-specific.
“This gives us the ability to look at the same toxicity question from both sides,” said Keith Murphy, Executive Chairman of VivoSim Labs. “If a compound is toxic in rats but not in our human liver model, that additional evidence may help sponsors better understand whether the finding is truly relevant to patients.”
The paired approach is intended to help pharmaceutical companies make more informed decisions about whether to advance, modify or further investigate a drug candidate, while adding human-relevant context to existing animal toxicology findings.
Rat toxicology remains widely used across large pharmaceutical development programs. VivoSim believes the new capability can complement those workflows and extend the commercial utility of its liver toxicology platform.
The Company plans to validate the rat model using compounds with known differences between rat and human liver toxicity.
“Differentiating true human risk from rat-specific liver toxicity is a major issue in preclinical development,” noted Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs. “Providing a side-by-side comparative model allows biopharma partners to protect assets from premature termination while avoiding failure costs. We believe this cross-species capability significantly broadens the market utility of our NAMkind™ platform and accelerates our commercial trajectory.”
VivoSim believes the addition could strengthen the Company’s position in liver toxicology by giving pharmaceutical customers a more complete way to interpret species differences before committing additional time and capital to development.
https://www.globenewswire.com/news-release/20...tform.html
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement its existing NAMkind™ human liver platform and expand the Company’s liver toxicology capabilities.
The new model is designed to address a longstanding challenge in drug development: toxicity observed in rats does not always translate to humans.
VivoSim’s current human liver model is designed to identify human toxicity that may not appear in animal studies. The planned rat model would add the reverse capability, helping sponsors determine when an adverse finding in rats may be species-specific.
“This gives us the ability to look at the same toxicity question from both sides,” said Keith Murphy, Executive Chairman of VivoSim Labs. “If a compound is toxic in rats but not in our human liver model, that additional evidence may help sponsors better understand whether the finding is truly relevant to patients.”
The paired approach is intended to help pharmaceutical companies make more informed decisions about whether to advance, modify or further investigate a drug candidate, while adding human-relevant context to existing animal toxicology findings.
Rat toxicology remains widely used across large pharmaceutical development programs. VivoSim believes the new capability can complement those workflows and extend the commercial utility of its liver toxicology platform.
The Company plans to validate the rat model using compounds with known differences between rat and human liver toxicity.
“Differentiating true human risk from rat-specific liver toxicity is a major issue in preclinical development,” noted Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs. “Providing a side-by-side comparative model allows biopharma partners to protect assets from premature termination while avoiding failure costs. We believe this cross-species capability significantly broadens the market utility of our NAMkind™ platform and accelerates our commercial trajectory.”
VivoSim believes the addition could strengthen the Company’s position in liver toxicology by giving pharmaceutical customers a more complete way to interpret species differences before committing additional time and capital to development.
